COVID-19 Prevention and Treatment in Cancer; a Sequential Multiple Assignment Randomised Trial;
Status:
Recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
A multi-centre Australian trial with four arms aims to evaluate several different immune
modulating drugs for prevention and treatment of COVID-19 specifically in the cancer
population.
ARM 1 is evaluating the effect of interferon-alpha (vs placebo) on the incidence of COVID-19
infection in cancer patients with no COVID-19 infection or no known COVID-19 positive
contacts.
ARM 2 is evaluating the effect of interferon-alpha (vs placebo) on the incidence of COVID-19
infection in cancer patients with confirmed exposure to COVID-19 virus.
ARM 3 is evaluating the effect of Selinexor (vs placebo) on the incidence of COVID-19
infection in cancer patients with moderate COVID-19 infection.
ARM 4 is evaluating the effect of Lenzilumab (vs placebo) on the treatment of COVID-19
infection in cancer patients with severe COVID-19 infection.
Participants may become eligible and transition to different arms and treatments if they
become exposed to COVID-19 or are hospitalised with an active moderate/severe COVID-19
infection.
It is hoped this research will provide insight into the best practice for prevention and
treatment of COVID-19 in cancer patients as emerging standard of care measures are not always
suitable to this especially vulnerable population.